Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “VEGFR2 Inhibitor”

27 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 27 results

Testing effectiveness (Phase 2)Ended earlyNCT06006923
What this trial is testing

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

Who this might be right for
MSI-H Colorectal Cancer
Anwaar Saeed 1
Early research (Phase 1)Study completedNCT01469052
What this trial is testing

First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors

Who this might be right for
Advanced Solid Tumors
Pfizer 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT06116890
What this trial is testing

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)
Kyowa Kirin Co., Ltd. 180
Early research (Phase 1)Study completedNCT00321581
What this trial is testing

AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia

Who this might be right for
Refractory or Recurrent Solid TumorsAcute Myelogenous Leukemia
National Cancer Institute (NCI) 18
Testing effectiveness (Phase 2)Looking for participantsNCT04645160
What this trial is testing

Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

Who this might be right for
CholangiocarcinomaBile Duct NeoplasmBiliary Tract Malignancy
National Cancer Institute (NCI) 31
Testing effectiveness (Phase 2)Study completedNCT00074867
What this trial is testing

Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer

Who this might be right for
Ovarian NeoplasmsPeritoneal NeoplasmsFallopian Tube Neoplasms
Pfizer 29
Early research (Phase 1)Ended earlyNCT00450879
What this trial is testing

Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery

Who this might be right for
Male Breast CarcinomaRecurrent Breast CarcinomaStage IA Breast Cancer+4 more
National Cancer Institute (NCI) 19
Testing effectiveness (Phase 2)WithdrawnNCT02747797
What this trial is testing

Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations

Who this might be right for
Advanced Cancer
Teresa Helsten, MD
Early research (Phase 1)Looking for participantsNCT04777994
What this trial is testing

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Who this might be right for
Advanced Solid Tumor Cancer
Calico Life Sciences LLC 248
Testing effectiveness (Phase 2)Study completedNCT00096239
What this trial is testing

CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Jonsson Comprehensive Cancer Center
Testing effectiveness (Phase 2)Study completedNCT03797326
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

Who this might be right for
Advanced Solid TumorsTriple Negative Breast CancerOvarian Cancer+5 more
Merck Sharp & Dohme LLC 611
Testing effectiveness (Phase 2)Looking for participantsNCT07049926
What this trial is testing

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

Who this might be right for
Renal Cell Carcinoma
Merck Sharp & Dohme LLC 140
Testing effectiveness (Phase 2)Active Not RecruitingNCT06116916
What this trial is testing

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

Who this might be right for
Diabetic Macular Edema (DME)
Kyowa Kirin Co., Ltd. 150
Not applicableStudy completedNCT00828919
What this trial is testing

Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials

Who this might be right for
Solid Tumors
Pfizer 52
Testing effectiveness (Phase 2)Study completedNCT00117299
What this trial is testing

PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib

Who this might be right for
Sarcoma
University of Helsinki 45
Large-scale testing (Phase 3)Study completedNCT01865747
What this trial is testing

Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma

Who this might be right for
Renal Cell Carcinoma
Exelixis 658
Testing effectiveness (Phase 2)Study completedNCT00725764
What this trial is testing

Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck

Who this might be right for
Neoplasms, Head and Neck
GlaxoSmithKline 14
Early research (Phase 1)Study completedNCT04393506
What this trial is testing

Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

Who this might be right for
Oral CancerVEGFR2 InhibitorProgrammed Cell Death 1 Inhibitor+1 more
Shanghai Jiao Tong University School of Medicine 21
Early research (Phase 1)Study completedNCT00375310
What this trial is testing

Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer

Who this might be right for
Pancreatic CancerAdenocarcinoma of the Pancreas
Indiana University 27
Testing effectiveness (Phase 2)Study completedNCT01068587
What this trial is testing

MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy

Who this might be right for
Lung Cancer
NCIC Clinical Trials Group 31
Next Page